Argos plummets on futility analysis of rocapuldencel-T for RCC

Argos Therapeutics Inc. (NASDAQ:ARGS) lost $2.93 (66%) to $1.48 on Wednesday after an independent DMC recommended discontinuing the Phase III ADAPT trial of rocapuldencel-T (AGS-003) to treat metastatic renal cell carcinoma. Argos said the trial will remain open while the company meets with FDA and conducts additional analyses. President and CEO Jeff Abbey said he expects next steps will be announced “in a few weeks.”

An interim analysis by the DMC determined that rocapuldencel-T plus standard of care (SOC), including Sutent sunitinib, was unlikely to meet the primary endpoint of improving overall survival (OS) vs. SOC alone. Rocapuldencel-T was generally well tolerated in the 462-patient trial...